entinostat has been researched along with Acute Lymphoid Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carraway, HE | 1 |
| Sawalha, Y | 1 |
| Gojo, I | 1 |
| Lee, MJ | 1 |
| Lee, S | 1 |
| Tomita, Y | 1 |
| Yuno, A | 1 |
| Greer, J | 1 |
| Smith, BD | 1 |
| Pratz, KW | 1 |
| Levis, MJ | 1 |
| Gore, SD | 1 |
| Ghosh, N | 1 |
| Dezern, A | 1 |
| Blackford, AL | 1 |
| Baer, MR | 1 |
| Gore, L | 1 |
| Piekarz, R | 1 |
| Trepel, JB | 1 |
| Karp, JE | 1 |
| Rivera-Del Valle, N | 1 |
| Cheng, T | 1 |
| Irwin, ME | 1 |
| Donnella, H | 1 |
| Singh, MM | 1 |
| Chandra, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995) Plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in A[NCT01132573] | Phase 1 | 27 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for entinostat and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Lineage; Clofarabine; | 2021 |
1 other study available for entinostat and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Topics: Adamantane; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; DNA Fragmentation; Drug | 2018 |